SCHEMBL2825532

SCHEMBL2825532

COc1ccc(-c2nnc3c4ccccc4c(Nc4ccc(C(=O)Nc5ccccc5)cc4)nn23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.54
LMNA P02545 2/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
TP53 P04637 1/20 0.54
POLB P06746 1/20 0.53
KDM4E B2RXH2 1/20 0.52
GSK3B P49841 1/20 0.51
PKM P14618 1/20 0.49
THRB P10828 1/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GABRA1 P14867 1/20 0.49
GABRG2 P18507 1/20 0.49
GABRB3 P28472 1/20 0.49
GABRA5 P31644 1/20 0.49
GABRA3 P34903 1/20 0.49
GABRA2 P47869 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2828235 0.98 MAPT (0.56) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2825724 0.98 MAPT (0.56) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2828040 0.97 MAPT (0.55) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2825351 0.93 MAPT (0.56) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2827702 0.93 MAPT (0.53) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2829703 0.92 MAPT (0.50) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2828630 0.92 MAPT (0.57) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2825087 0.91 MAPT (0.57) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2832052 0.91 MAPT (0.56) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL2827889 0.91 MAPT (0.61) MAPTLMNANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851472-B2 Triazolophthalazines NYCOMED GMBH (DE) 2010-12-14 US disclosed
US-20100286140-A1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-11-11 US disclosed
EP-1791543-B1 TRIAZOLOPHTHALAZINES NYCOMED GMBH (DE) 2010-06-16 EP disclosed
US-20090005372-A1 Triazolophthalazines ALTANA PHARMA AG (DE) 2009-01-01 US disclosed
EP-1791543-A2 TRIAZOLOPHTHALAZINES Altana Pharma AG (DE) 2007-06-06 EP disclosed
WO-2006024640-A2 TRIAZOLOPHTHALAZINES ALTANA PHARMA AG (DE) 2006-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286140-A1 TRIAZOLOPHTHALAZINES PDE2A, PDE12, PDE3A MAPT 3816/4885LMNA 3740/4885NPC1 3556/4885
US-20090005372-A1 Triazolophthalazines PDE2A, PDE12, PDE3A MAPT 3816/4885LMNA 3740/4885NPC1 3556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.